AZD 9139Alternative Names: AZD9139
Latest Information Update: 22 Feb 2005
At a glance
- Originator AstraZeneca
- Class Gastrokinetics
- Mechanism of Action Potassium-competitive acid blockers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 27 Jan 2005 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (unspecified route)
- 20 Oct 2004 Preclinical trials in Gastro-oesophageal reflux in Europe (unspecified route)